Prevent Blindness America names board members
September 15th 2002Schaumburg, IL-Prevent Blindness America (PBA) appointed two new board members to its 2002-2003 national board of directors: Dan Myers of Duluth, GA, who is president of Novartis Ophthalmic's North American Division, and Julian Gangolli of Laguna Niguel, CA, who is senior vice president of U.S. eye care sales and marketing, Allergan.
Macugen research: Enrollment ends early in trials for wet AMD drug
September 15th 2002New York-Eyetech Pharmaceuticals Inc. has completed enrollment in two phase III trials of Macugen, its treatment for wet age-related macular degeneration (AMD), and has received $54.2 million from investors for further development of the drug.
No appeal process: HHS refusal to cover AMD therapy sparks suit
September 15th 2002Washington, DC-Several organizations have joined three patients with age-related macular degeneration (AMD) in a lawsuit filed against the Department of Health and Human Services in an effort to appeal the department's ruling that Medicare would not cover ocular photodynamic therapy (PDT) with verteporfin.
Myopia cases on rise: 30-day lenses might offer alternative to LASIK
September 15th 2002Sydney, Australia-A rapid increase in the occurrence of myopia and an aging world population means 70% of the world will require vision correction by year 2020, according to a study by the Cooperative Research Centre for Eye Research and Technology.
Evaluation of third nerve palsy remains problematic
September 1st 2002It's 4:55 p.m. on a Friday, last patient of the day-a 50-year-old man with diabetes and hypertension with new-onset right-sided ptosis and diplopia. Examination reveals a right third nerve palsy (TNP). What is the next most appropriate step?
Microphaco technology safely separates irrigation, aspiration
September 1st 2002Philadelphia-Twenty-one gauge microphaco performed with WhiteStar Technology (Advanced Medical Optics, Santa Ana, CA) that uses two microincisions (0.8 mm) to separate irrigation and aspiration is safe, according to Randall Olson, MD.
Getting a clearer vision of the refractive marketplace
September 1st 2002Sacramento, CA-As the boom in LASIK surgery recedes, refractive surgeons risk major declines in numbers of patients unless they understand marketing concepts that will help them find and attract potential clients, according to Glenn Hagele.
Uveitis Update: Medical, surgical options considered for uveitic glaucoma
September 1st 2002Editor's Note: Uveitic glaucoma is often not a single disease. Multiple factors, including inflammatory mediators as well as anatomic/morphologic changes, can contribute to the development of elevated IOP. Corticosteroids used to treat the inflammation can also produce elevated IOP. It is important to try to sort out these factors in patients with uveitic glaucoma to determine what category they fit in, and then select the best treatment.
Benefits of bifocal contact lens may depend on aberrations
September 1st 2002Fort Lauderdale, FL-Researchers at the University of Houston College of Optometry are trying to understand why certain individuals do not gain bifocal vision with a multizone bifocal contact lens. The reason could be dependent on an individual's optical aberrations, noted Joy A. Martin, an OD and PhD student, who spoke during the annual meeting of the Association for Research in Vision and Ophthalmology.
Survey suggests better glaucoma regimen needed
September 1st 2002London: A survey by the International Glaucoma Association (IGA) of 243 European patients and 250 physicians found that a significant number of patients with glaucoma experienced difficulties taking multiple medications, indicating a need for better education about the disease and its treatment options.
Blue-blocking lens closely mimics human crystalline lens
August 15th 2002Philadelphia-The clinical results with a new, single-piece Blue Blocking AcrySof IOL (SB30, Alcon) that mimics the light transmission spectrum of a human natural crystalline lens indicate that it is safe and effective. The visual results were comparable to those obtained with the SA30 lens (Alcon) that served as a control.
Technology reduces thermal injury in small-incision surgery
August 15th 2002Philadelphia-Ultrasound energy and time are eliminated with the development of Aqualase technology (Alcon) for small-incision cataract surgery. Robert Lehmann, MD, reported on the advancement of this liquefaction technology here at the annual meeting of the American Society of Cata-ract and Refractive Surgery.
Early results promising for two IOLs with sharp-edged optics
August 15th 2002Philadelphia-A new silicone IOL and a new hydrophobic acrylate lens are both easy and safe to implant, offering reliable refraction for patients with high myopia and high hyperopia, said Gerd U. Auffarth, MD, at the American Society of Cataract and Refractive Surgery annual meeting here.
Brunescent lenses removed safely, effectively with cold phaco
August 15th 2002Philadelphia-The Sovereign WhiteStar system is a revolutionary "cold" phaco technology that is unique in its ability to emulsify the most brunescent nuclei without any risk of a wound burn, according to David F. Chang, MD, who reported on his experience with WhiteStar (AMO, Irvine, CA) here at the annual meeting of the American Society of Cataract and Refractive Surgery.
Patients satisfied with improved contrast sensitivity of IOL
August 15th 2002Philadelphia-The Tecnis Z9000 IOL (Pharmacia) performed well in a clinical trial by providing improved contrast sensitivity compared with a conventional IOL. In addition, in a model eye the Tecnis IOL also improved the optical performance by compensating for corneal aberrations.
Pre-rolled implant offers a novel optic-edge design
August 15th 2002Philadelphia-The CV232 Square-Round-Edge (SRE) IOL, the newest-generation pre-rolled implant from CIBA Vision, combines all of the advantages of its predecessor model (MemoryLens) with the best of both worlds in optic-edge design, said Matteo Piovella, MD, at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS).
Louis Emile Javal contributed to field before, after blindness
August 15th 2002Editor's Note: About 100 years ago, Louis Emile Javal, MD (1839-1907), suffered blindness as a result of glaucoma. Thebest medical minds of the day could not stave off these results. Medicine and surgery were used in vain. The accomplishments of this great ophthalmologist both before and after his blindness are discussed in this month's column.